Talphera TLPH
NASDAQ TLPH
$1.24 +0.01 (+1.23%)
As of: Sep 10, 2026 · 1:39 PM EDT

Talphera (TLPH) Income from Continuing Operations (2010 - 2026)

Talphera (TLPH) posted Income from Continuing Operations of -$3.8 million for Q2 2026, up 0.71% on a QoQ basis from -$3.8 million in Q1 2026, and down 3.93% year-over-year from -$3.9 million in Q2 2025.

Analysis

Talphera (TLPH) Income from Continuing Operations (2010 - 2026) Analysis & Trends

Talphera has reported Income from Continuing Operations for 17 years, with the latest figure at -$3.8 million in Q2 2026.

  • On a quarterly basis, Income from Continuing Operations fell 3.93% year-over-year to -$3.8 million in Q2 2026; TTM through Jun 2026 was -$14.1 million, a 11.17% decrease from a year earlier, with the FY2025 full-year figure at -$13.0 million, up 10.46% from the prior year.
  • Income from Continuing Operations was -$3.8 million for Q2 2026 at Talphera, up from -$3.8 million in the prior quarter.
  • The five-year high for Income from Continuing Operations was $70.7 million in Q2 2022, with the low at -$9.3 million in Q1 2022.
  • Average Income from Continuing Operations over 5 years is $428000.0, with a median of -$3.6 million recorded in 2025.
  • The largest YoY upside for Income from Continuing Operations was 817.32% in 2022 against a maximum downside of 1031.37% in 2022.
  • Over 5 years, Income from Continuing Operations stood at -$6.1 million in 2022, then soared by 89.51% to -$643000.0 in 2023, then tumbled by 349.92% to -$2.9 million in 2024, then fell by 12.34% to -$3.2 million in 2025, then declined by 15.45% to -$3.8 million in 2026.
  • The last three Income from Continuing Operations figures came in at -$3.8 million (Q2 2026), -$3.8 million (Q1 2026), and -$3.2 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 180.02 Bn 176.84 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 131.54 Bn 123.69 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 81.96 Bn 73.96 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 60.23 Bn 55.04 Bn 1.37 Bn 601.00 Mn
6 Moderna 53.85 Bn 48.72 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 33.13 Bn 29.82 Bn 992.69 Mn 164.49 Mn
8 Biogen 31.88 Bn 30.59 Bn 1.96 Bn 97.50 Mn
9 Roivant Sciences 29.23 Bn 29.23 Bn 1.16 Mn -290.61 Mn
10 Talphera 93.28 Mn 93.28 Mn - -3.75 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -3.75 Mn
Mar 31, 2026 -3.78 Mn
Dec 31, 2025 -3.25 Mn
Sep 30, 2025 -3.34 Mn
Jun 30, 2025 -3.61 Mn
Mar 31, 2025 -2.85 Mn
Dec 31, 2024 -2.89 Mn
Sep 30, 2024 -3.35 Mn
Jun 30, 2024 -3.83 Mn
Mar 31, 2024 -4.02 Mn
Dec 31, 2023 -643,000.00
Sep 30, 2023 -1.42 Mn
Jun 30, 2023 -4.43 Mn
Dec 31, 2022 -6.13 Mn
Sep 30, 2022 -6.75 Mn
Jun 30, 2022 70.66 Mn
Mar 31, 2022 -9.35 Mn
Dec 31, 2021 -542,000.00
Sep 30, 2021 -8.38 Mn
Jun 30, 2021 -9.85 Mn